Studies show that AML patients with high expression of conventional immune checkpoints (such as PD1, CD274, and CTLA4) did not benefit from immunotherapy, and these are closely related to immune complications (Berger et al., 2008; Chen et al., 2020). The gene discussed is CTLA4; the disease is acute myeloid leukemia.